PETACH TIKVA, Israel, November 3, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Photo: http://photos.prnewswire.com/prnh/20161103/435811 )
The Investor will be issued with 2,307,692 restricted shares of the Company's common stock (a price of $0.13 per share) with additional warrants to purchase 761,538 restricted shares at an exercise price of $0.25 per share for a period of 24 months, and additional warrants for 761,538 restricted shares at an exercise price of $0.40 per share for a period of 36 months. In addition to the investment, the parties will establish a joint venture, 75% to OWCP and 25% to Michepro Holding Ltd to promote, sell, market and distribute the Company's potential products in Europe, initially with the psoriasis treatment, to be followed with company's other therapies as they become available."
The World Health Organization's 2016 Global Report on Psoriasis states that psoriasis is a serious global problem affecting at least 100 million individuals worldwide. The report indicates the prevalence of psoriasis ranges from 0.09% in countries with warmer climates to 11.43% in Norway, where a colder climate prevails. The European market for psoriasis is estimated to be 15-20 Million patients.
Mr. Mordechai Bignitz, OWCP's Chairman and CEO, commented on the announcement, "We are excited to partner with Michepro Holding Ltd. The investment proceeds will be used to accelerate development of several of OWCP's products and support international marketing activities". Mr. Bignitz went on to say: "the recent activity in OWC stock has given rise to numerous investment proposals, but after reviewing the options we believe that Michepro Holding Ltd represents the best opportunity for the Company and our shareholders. Their EU business development experience and marketing expertise, as well as their enthusiasm about our future as a company are very encouraging, and it is the perfect follow-up to the agreement with signed with MedMar for the US."
Mr. Bignitz competed, "We believe the European market represents a substantial opportunity. Medical cannabis is already administrated in some countries in Europe, with several markets indicating they are on the brink of approval. Our initial focus will be the Netherlands, Czech Republic, Italy, Germany and the UK."
Commenting on his investment, Mr. Michael Brath a Director of Michepro Holding Ltd said, "OWC is the perfect match to our investment strategy; they are pioneers in the field of medical cannabis clinical research and we see incredible value in the work they are doing which is exactly what has been missing from thisMMJ market. We decided to invest and partner with them because I believe that our resources across the EU will significantly accelerate their ability to commercialize those efforts throughout that market - initially with the psoriasis treatment, and then with other therapies as they come online"
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information: In Israel: Ziv Turner, Chief Executive Officer - One World Cannabis Ltd. Email: firstname.lastname@example.org Tel: +972-(0)3-7582659 In the United States: Jeffrey Friedland Email: Jfriedland@owcpharma.com Tel: +1-(646)-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All